Role of Molecular Imaging in Oncology
DOI:
https://doi.org/10.17140/CSMMOJ-1-e001Keywords:
Antibody, Imaging, SPECT, PET, Tumor, OpticalAbstract
Molecular Imaging (MI) is an emerging technology for the early detection of disease, staging of the disease, and for monitoring response to therapy. It also offers a non-invasive method to detect in vivo biological functions and processes at a molecular level. The use of MI requires careful selection of targeting molecules which are expressed differentially in diseased vs. healthy cells to interrogate the cell microenvironment. Targeting molecules for MI could consist of small molecules, single amino acid units, low molecular weight peptides, antibodies or antibody fragments. Over the years, a large number of small molecular weight imaging probes have been developed to target different molecular pathways using Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). The use of high molecular weight probes such as radioactive antibodies (Ab) is also equally attractive. While a major effort is placed on developing radioactive probes for PET and SPECT imaging, an intense effort is being focused on enhancing the utility of other MI modalities such as nuclear Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS), Computed Tomography (CT), optical imaging and ultrasound (US).
References
Blasberg RG. Imaging update: new windows, new views. Clin Cancer Res. 2007; 13(12): 3444-3448. doi: 10.1158/1078-0432. CCR-07-0936
Herscovitch P, Mintun MA, Raichle ME. Brain oxygen utili-zation measured with oxygen-15 radiotracers and positron emis-sion tomography: generation of metabolic images. J Nucl Med. 1985; 26: 416-417.
Stocklin G. Tracers for metabolic imaging of brain and heart— radiochemistry and radiopharmacology. Eur J Nucl Med. 1992; 19(7): 527-551.
Agool A, SR, Kluin PM, de Wolf JT, Dierckx RA, Vellenga E. F-18 FLT PET: a non-invasive diagnostic tool for visulaiza-tion of the bone marrow compartment in patients with aplastic anemia: a pilot study. Clin Nucl Med. 2011; 36(4): 286-289. doi: 10.1097/RLU.0b013e31820aa1a1
Katzenellenbogen JA, Welch MJ, Dehdashti F. The develop-ment of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Research. 1997; 17(3B): 1573-1576.
Fried D, Garg S, Thomas A, et al. Monitoring treatment re-sponse inhigh risk prostate cancer patients using C-11 choline PET/CT. J Nucl Medicine Mol Imaging. 2010; 51: 51P.
Li X, Liu Q, Wang, et al. C-11 choline PET/CT imag-ing for differentiating malignant from benign prostate le-sions. Clin Nucl Med. 2008; 33(10): 671-676. doi: 10.1097/ RLU.0b013e318184b3a0
Rottenburger C, Hentschel M, Kelly T, et al. Comparison of C-11 methionine and C-11 choline for PET imaging of brain me-tastases: a prospective pilot study. Clin Nucl Med. 2011; 36(8): 639-642. doi: 10.1097/RLU.0b013e3182175840
Shinoura N, Nishijima M, Hara T, et al. Brain tumors: detec-tion with C-11 choline PET. Radiology. 1997; 202(2): 497-503. doi: 10.1148/radiology.202.2.9015080
Mease RC. Radionuclide based imaging of prostate can-cer. Curr Top Med Chem. 2010; 10(16): 1600-1616. doi: http:// dx.doi.org/10.2174/156802610793176774
Reske SN. Nuclear imaging of prostate cancer: current sta-tus. Urologe A. 2007; 46(11): 1485-1499. doi: 10.1007/s00120- 007-1572-6
Mendichovszky I, Jackson A. Imaging hypoxia in gliomas. Br J Radiol. 2011; 84 Spec No 2: S145-S158. doi: 10.1259/ bjr/82292521
Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging ox-ygenation of human tumours. Eur Radiol. 2007; 17(4): 861- 872. doi: 10.1007/s00330-006-0431-y
Collingridge DR, Glaser M, Osman S, et al. In vitro selec-tivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Can-cer. 2003; 89(7): 1327-1333. doi: 10.1038/sj.bjc.6601262
Li X, Link JM, Stekhova S, et al. Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug Chem. 2008; 19(8): 1684-1688. doi: 10.1021/bc800164d
Garg PK, Labaree DC, Hoyte RM, Hochberg RB. [7a-18F]Fluoro-17a-methyl-5a-dihydrotestosterone: a ligand for androgen receptor-mediated imaging of prostate cancer. Nucl Med Biol. 2001; 28(1): 85-90.
Garg S, Doke A, Black KW, Garg PK. In vivo biodistribu-tion of an androgen receptor avid PET imaging agent 7-alpha-fluoro-17 alpha-methyl-5-alpha-dihydrotestosterone ([(18)F] FMDHT) in rats pretreated with cetrorelix, a GnRH antago-nist. Eur J Nucl Med Mol Imaging. 2008; 35(2): 379-385.
Ponde DE, Dence CS, Schuster DP, Welch MJ. Rapid and reproducible radiosynthesis of [18F] FHBG. Nucl Med Biol. 2004; 31(1): 133-138. doi: 10.1016/S0969-8051(03)00096-9
Lee YL, Lee YJ, Ahn SJ, et al. Combined radionuclide-chemotherapy and in vivo imaging of hepatocellular carci-noma cells after transfection of a triple-gene construct, NIS, HSV1-sr39tk, and EGFP. Cancer Lett. 2010; 290(1): 129-138. doi: 10.1016/j.canlet.2009.09.004
Qiao H, Surti S, Choi SR, et al. Death and proliferation time course of stem cells transplanted in the myocardium. Mol Imaging Biol. 2009; 11(6): 408-414. doi: 10.1007/s11307-009- -0222-3
Giovacchini G, Samanes Gajate AM, Messa C, Fazio F. Increased C-11 choline uptake in pagetic bone in a pa-tient with coexisting skeletal metastases from prostate can-cer. Clin Nucl Med. 2008; 33(11): 797-798. doi: 10.1097/ RLU.0b013e318187ee35
Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998; 39(6): 990-995.
Hara T, Kosaka N, Kondo T, et al. Imaging of brain tumor, lung cancer, esophagus cancer, colon cancer, prostate cancer, and bladder cancer with [11C]choline [Abstract]. J Nucl Med. 1997; 38: 250P.
Attia A, V GT, Garg PK, et al. The utility of C-11 choline PET/CT for staging advanced esophageal cancer. Int J Radiat Biol Phys. 2011; 81: S314.
Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004; 45(3): 366-373.
DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001; 42(12): 1805-1814.
Garg S, Lynch AJ, Doke AK, Minton RC, Garg PK. A remote controlled system for the preparation of 7 alpha-[18F]fluoro-17 alpha-methyl 5 alpha-dihydrotestosterone ([18F]FMDHT) us-ing microwave. Appl Radiat Isot. 2008; 66(5): 612-618. doi: 10.1016/j.apradiso.2008.01.017
van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007; 12(12): 1379- 1389. doi: 10.1634/theoncologist.12-12-1379
Fakih MG, Padmanabhan A. CEA monitoring in colorec-tal cancer. What you should know. Oncology (Williston Park). 2006; 20(6): 579-587; discussion 588, 594, 596 passim.
Grote T, Siwak DR, Fritsche HA, et al. Validation of reverse phase protein array for practical screening of potential biomark-ers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics. 2008; 8(15): 3051-3060. doi: 10.1002/pmic.200700951
Wiernik PH. Serum CA125 and PSA concentrations in pa-tients with lymphoma. Clin Adv Hematol Oncol. 2008; 6(7): 527-531.
Kalofonos HP, Karamouzis MV, Epenetos AA. Radioim-munoscintigraphy in patients with ovarian cancer. Acta Oncol. 2001; 40(5): 549-557.
Keane TE, Rosner IL, Wingo MS, McLeod DG. The emer-gence of radioimmunoscintigraphy for prostate cancer. Rev Urol. 2006; 8 Suppl 1: S20-S28.
Brassell SA, Rosner IL, McLeod DG. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer. Curr Opin Urol. 2005; 15(3): 163-166.
Sundaresan G, Yazaki PJ, Shively JE, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-con-trast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003; 44(12): 1962-1969.
Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005; 46 Suppl 1: 164S-171S.
Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal anti-bodies. J Nucl Med. 2003; 44(8): 1271-1281.
Verel I, Visser GW, Vosjan MJ, Finn R, Boellaard R, van Dongen GA. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunothera-py. Eur J Nucl Med Mol Imaging. 2004; 31(12): 1645-1652. doi: 10.1007/s00259-004-1632-8
Verel I, Visser GW, Boellaard R, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003; 44(10): 1663-1670.
Penuelas I, Haberkorn U, Yaghoubi S, Gambhir SS. Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging. 2005; 32 Suppl 2: S384-S403. doi: 10.1007/s00259-005-1928-3
Ogawa M, Kosaka N, Choyke PL, Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared flu-orescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res. 2009; 69(4): 1268-1272. doi: 10.1158/0008-5472.CAN-08-3116
Dijkmans PA, Juffermans LJ, Musters RJ, et al. Microbub-bles and ultrasound: from diagnosis to therapy. Eur J Echocar-diogr. 2004; 5(4): 245-256. doi: http://dx.doi.org/10.1016/j. euje.2004.02.001
Lindner JR. Microbubbles in medical imaging: current appli-cations and future directions. Nat Rev Drug Discov. 2004; 3(6): 527-532. doi: 10.1038/nrd1417
Lanza GM, Wallace KD, Scott MJ, et al. A novel site-tar-geted ultrasonic contrast agent with broad biomedical applica-tion. Circulation. 1996; 94(12): 3334-3340. doi: 10.1161/01. CIR.94.12.3334
Unger EC, McCreery TP, Sweitzer RH, Shen D, Wu G. In vitro studies of a new thrombus-specific ultrasound contrast agent. Am J Cardiol. 1998; 81(12A): 58G-61G. doi: 10.1016/ S0002-9149(98)00055-1
Niu Z, Fang Y. Surface-enhanced Raman scattering of sin-gle-walled carbon nanotubes on silver-coated and gold-coated filter paper. J Colloid Interface Sci. 2006; 303(1): 224-228. doi: 10.1016/j.jcis.2006.07.039
Nie S, Emory SR. Probing Single Molecules and Single Nanoparticles by Surface-Enhanced Raman Scattering. Science. 1997; 275(5303): 1102-1106. doi: 10.1126/science.275.5303.1102
Zavaleta CL, Smith BR, Walton I, et al. Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice us-ing noninvasive Raman spectroscopy. Proc Natl Acad Sci U S A. 2009; 106(32): 13511-13556. Cancer Stud Mol Med Open J Page e7
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
